An array of immunotherapeutic strategies for B-cell lymphomas

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• Monoclonal antibodies (mAbs) targeting CD20 have gained FDA approval, advancing immunotherapy for B-cell non-Hodgkin's-lymphomas (NHL).
• Over 20 years have passed since the initial description of CD20 mAbs, leading to their current implementation in treatment.
• NHL research is active, with numerous novel immunotherapeutic strategies under development.

Purpose of the Study:

• To review the evolving landscape of immunotherapy for B-cell non-Hodgkin's-lymphomas.
• To highlight advancements in both passive immunotherapy (mAbs) and active immunotherapy (vaccines, T-cell therapies).
• To discuss the potential of combining various immunotherapeutic approaches for improved NHL treatment.

Main Methods:

• Review of approved and investigational therapies including unconjugated and radioconjugated mAbs.
• Analysis of ongoing clinical trials for adoptive T-cell transfer and antisense approaches.
• Examination of refined vaccination strategies targeting clonal idiotype and universal tumor antigens.

Main Results:

• Monoclonal antibodies (mAbs) are approved or in Phase III trials with promising results.
• Adoptive T-cell transfer and antisense therapies are in early-phase clinical trials.
• Vaccine strategies, including those targeting idiotype and cellular vaccines, are showing clinical applicability and progress.

Conclusions:

• Immunotherapy for B-cell malignancies is rapidly evolving with diverse and promising strategies.
• The combination of passive and active immunotherapy approaches may lead to standard treatment modalities for NHL.
• Continued research and clinical trials are crucial for realizing the full potential of immunotherapy in treating B-cell non-Hodgkin's-lymphomas.